Open AccessPrimary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer
Author(s) -
John R. Mackey,
Manuel Ramos-Vázquez,
Oleg Lipatov,
Nicole McCarthy,
Dmitriy Krasnozhon,
Semiglazov Vf,
Alexey Manikhas,
Karen A. Gelmon,
Gottfried E. Konecny,
Marc Webster,
Roberto Hegg,
Sunil Verma,
Vera Gorbunova,
Dany Abi Gerges,
Francois Thireau,
Helena Fung,
Lorinda Simms,
Marc Buyse,
Ayman Ibrahim,
Miguel Martín
Publication year - 2014
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2014.57.1513
Subject(s) - ramucirumab , docetaxel , medicine , metastatic breast cancer , oncology , hazard ratio , clinical endpoint , taxane , breast cancer , placebo , chemotherapy , progression free survival , cancer , randomized controlled trial , pathology , confidence interval , alternative medicine
Currently, antiangiogenic strategies in metastatic breast cancer have demonstrated modest improvements in progression-free survival (PFS) but not improved quality or duration of survival, warranting evaluation of new agents in a placebo-controlled setting. Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks ligand-stimulated activation. The ROSE/TRIO-012 trial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom